In-depth: SA’s remarkable TB clinical trial capacity

Several of the world’s most important tuberculosis clinical trials of the last two decades were done in part or entirely in South Africa. Tiyese Jeranji chatted to some leading researchers about where the country’s clinical trial capacity comes from and what is needed to maintain and improve it.

Read More

Face to face: “Fail your way to success”, says Prof behind pioneering drug discovery group at UCT

Technical work on the discovery of new medicines is not commonly done in South Africa, or Africa, for that matter. One person who is at the forefront of changing this, is Kelly Chibale, a professor in organic chemistry and founder of the pioneering Holistic Drug Discovery and Development Centre – H3D – at the University of Cape Town. Biénne Huisman spoke to Chibale about his fascinating work and his journey from a village in Zambia, across the world, and back to Cape Town.

Read More

In-depth: How a Cape Town company made an mRNA vaccine and what happens next

In January, Cape Town-based biotechnology company Afrigen Biologics announced that it has successfully produced a lab-scale batch of a mRNA vaccine against COVID-19 that is similar to that made by pharmaceutical company Moderna. Catherine Tomlinson takes an in-depth look at how Afrigen managed to reach this point and what further challenges have to be overcome before mRNA vaccines can be produced at scale in South Africa

Read More

OPINION: Going Local in Health Innovation – It is time and we are ready

The COVID-19 pandemic has reinforced the need to think global and build locally. The African innovative pharmaceutical sector has the potential to thrive and needs more incentive to grow. A blooming continental sector would serve as a critical and secure source for key vaccines and therapeutics, reducing the need to rely on the goodwill of donors, writes Professor Kelly Chibale.

Read More

Analysis: How do you price a life-saving vaccine during a pandemic?

In late January, Dr Anban Pillay, Deputy Director-General in South Africa’s National Department of Health, revealed that South Africa would pay more than double the price paid by the European Union (EU) for AstraZeneca’s COVID-19 vaccine. This set off a flurry of questions on how vaccine prices are set and why, in many cases, the prices themselves are not known to the public. Catherine Tomlinson takes a closer look at the issues involved.

Read More

Teamwork and infrastructure behind local malaria discovery, researchers say

Local scientists, as part of an international research collaboration, identified chemical compounds with antitubercular and anti-cancer properties that could potentially help in the fight against malaria. The compounds could halt a malaria parasite in its tracks during different stages of the parasite’s life cycle. Kathryn Cleary interviewed two of the researchers about the scientific discovery and the teamwork and infrastructure that made it possible.

Read More

COVID-19: How vaccine registration will work in SA

Before any COVID-19 vaccines can be made available in South Africa, they must be authorised by South Africa’s medicines regulator—the South African Health Products Regulatory Authority (SAHPRA). Catherine Tomlinson explores how SAHPRA is preparing to review and authorise the use of COVID-19 vaccines in the country and the different authorisation approaches they may use.

Read More

IN-DEPTH: The slow motion race for a TB vaccine

In recent months, the world has seen unprecedented investment in new vaccines. Yet, while a COVID-19 vaccine proven to be safe and effective may be less than a year away, a new tuberculosis vaccine might only be ready to be rolled out in a decade, despite a massive head start over COVID-19. Amy Green takes a closer look at the race for a new vaccine for the world’s top infectious disease killer.

Read More

1.3m switched to new ARV, but weight gain is a concern

Two years after it was announced that the ARV dolutegravir would become part of standard first line HIV treatment in South Africa, it is finally reaching significant numbers of people. But new research about a worrying side-effect, weight gain (particularly in women), has muddied its otherwise stellar reputation.

Read More